Trajectory of NAFLD characteristics after Roux-en-Y gastric bypass
a five-year historical cohort study
Keywords:
Gastric bypass, Bariatric surgery, Obesity, Fatty liverAbstract
BACKGROUND: The long-term effects of bariatric surgery on the course of non-alcoholic fatty hepatopathy (NAFLD) are not fully understood. OBJECTIVE: To analyze the evolution of NAFLD characteristics through noninvasive markers after Rouxen-Y gastric bypass (RYGB) over a five-year period. DESIGN AND SETTING: Historical cohort study; tertiary-level university hospital. METHODS: The evolution of NAFLD-related characteristics was evaluated among 49 individuals who underwent RYGB, with a five-year follow-up. Steatosis was evaluated through the hepatic steatosis index (HSI), steatohepatitis through the clinical score for non-alcoholic steatohepatitis (C-NASH) and fibrosis through the NAFLD fibrosis score (NFS). RESULTS: 91.8% of the individuals were female. The mean age was 38.3 ± 10 years and average body mass index (BMI), 37.4 ± 2.3 kg/m2. HSI significantly decreased from 47.15 ± 4.27 to 36.03 ± 3.72 at 12 months (P < 0.01), without other significant changes up to 60 months. C-NASH significantly decreased from 0.75 ± 1.25 to 0.29 ± 0.7 at 12 months (P < 0.01), without other significant changes up to 60 months. NFS decreased from 1.14 ± 1.23 to 0.27 ± 0.99 at 12 months (P < 0.01), and then followed a slightly ascending course, with a marked increase by 60 months (0.82 ± 0.89), but still lower than at baseline (P < 0.05). HSI variation strongly correlated with the five-year percentage total weight loss (R = 0.8; P < 0.0001). CONCLUSION: RYGB led to significant improvement of steatosis, steatohepatitis and fibrosis after five years. Fibrosis was the most refractory abnormality, with a slightly ascending trend after two years. Steatosis improvement directly correlated with weight loss.
Downloads
References
Younossi ZM. Non-alcoholic fatty liver disease - A global public health perspective. J Hepatol. 2019;70(3):531-44. PMID: 30414863; https://doi.org/10.1016/j.jhep.2018.10.033
Younossi Z, Tacke F, Arrese M, et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology. 2019;69(6):2672-82. PMID: 30179269; https://doi.org/10.1002/hep.30251
Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. PMID: 28714183; https://doi.org/10.1002/hep.29367
Piazzolla VA, Mangia A. Noninvasive Diagnosis of NAFLD and NASH. Cells. 2020;9(4):1005. PMID: 32316690; https://doi.org/10.3390/cells9041005
Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397(10271):293-304. PMID: 33485454; https://doi.org/10.1016/S0140-6736(20)32649-0.
Conte C, Lapeyre-Mestre M, Hanaire H, Ritz P. Diabetes Remission and Relapse After Bariatric Surgery: a Nationwide Population-Based Study. Obes Surg. 2020;30(12):4810-20. PMID: 32869127; https://doi.org/10.1007/s11695-020-04924-3.
Concon MM, Jimenez LS, Callejas GH, Chaim EA, Cazzo E. Influence of post-Roux-en-Y gastric bypass weight recidivism on insulin resistance: a 3-year follow-up. Surg Obes Relat Dis. 2019;15(11):1912-6. PMID: 31631000; https://doi.org/10.1016/j.soard.2019.08.023.
Cotrim HP, Parise ER, Oliveira CP, et al. Nonalcoholic fatty liver disease in Brazil. Clinical and histological profile. Ann Hepatol. 2011;10(1):33-7. PMID: 21301007.
Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-21. PMID: 15915461; https://doi.org/10.1002/hep.20701.
Cazzo E, Pareja JC, Chaim EA. Nonalcoholic fatty liver disease and bariatric surgery: a comprehensive review. Sao Paulo Med J. 2017;135(3):277-95. PMID: 28562737; https://doi.org/10.1590/1516-3180.2016.0306311216.
Magro DO, Ueno M, Coelho-Neto JS, et al. Long-term weight loss outcomes after banded Roux-en-Y gastric bypass: a prospective 10-year follow-up study. Surg Obes Relat Dis. 2018;14(7):910-7. PMID: 29706496; https://doi.org/10.1016/j.soard.2018.03.023.
Mehaffey JH, LaPar DJ, Clement KC, et al. 10-Year Outcomes After Roux-en-Y Gastric Bypass. Ann Surg. 2016;264(1):121-6. PMID: 26720434; https://doi.org/10.1097/SLA.0000000000001544.
Uehara D, Seki Y, Kakizaki S, et al. Long-term Results of Bariatric Surgery for Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis Treatment in Morbidly Obese Japanese Patients. Obes Surg. 2019;29(4):1195-201. PMID: 30542827; https://doi.org/10.1007/s11695-018-03641-2.
Mathurin P, Hollebecque A, Arnalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137(2):532-40. PMID: 19409898; https://doi.org/10.1053/j.gastro.2009.04.052.
Yoshioka N, Ishigami M, Watanabe Y, et al. Effect of weight change and lifestyle modifications on the development or remission of nonalcoholic fatty liver disease: sex-specific analysis. Sci Rep. 2020;10(1):481. PMID: 31949229; https://doi.org/10.1038/s41598-019-57369-9.
VanWagner LB, Khan SS, Ning H, et al. Body mass index trajectories in young adulthood predict non-alcoholic fatty liver disease in middle age: The CARDIA cohort study. Liver Int. 2018;38(4):706-14. PMID: 28963767; https://doi.org/10.1111/liv.13603.
Bower G, Toma T, Harling L, et al. Bariatric Surgery and Non-Alcoholic Fatty Liver Disease: a Systematic Review of Liver Biochemistry and Histology. Obes Surg. 2015;25(12):2280-9. PMID: 25917981; https://doi.org/10.1007/s11695-015-1691-x.
Lassailly G, Caiazzo R, Ntandja-Wandji LC, et al. Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis. Gastroenterology. 2020;159(4):1290-1301.e5. PMID: 32553765; https://doi.org/10.1053/j.gastro.2020.06.006.
Yeo SC, Ong WM, Cheng KSA, Tan CH. Weight Loss After Bariatric Surgery Predicts an Improvement in the Non-alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score. Obes Surg. 2019;29(4):1295-300. PMID: 30635812; https://doi.org/10.1007/s11695-018-03676-5.
Fakhry TK, Mhaskar R, Schwitalla T, et al. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019;15(3):502-11. PMID: 30683512; https://doi.org/10.1016/j.soard.2018.12.002.
Cazzo E, Jimenez LS, Pareja JC, Chaim EA. Effect of Roux-en-Y gastric bypass on nonalcoholic fatty liver disease evaluated through NAFLD fibrosis score: a prospective study. Obes Surg. 2015;25(6):982-5. PMID: 25381118; https://doi.org/10.1007/s11695-014-1489-2.
Jimenez LS, Mendonça Chaim FH, Mendonça Chaim FD, et al. Impact of Weight Regain on the Evolution of Non-alcoholic Fatty Liver Disease After Roux-en-Y Gastric Bypass: a 3-Year Follow-up. Obes Surg. 2018;28(10):3131-5. PMID: 29725976; https://doi.org/10.1007/s11695-018-3286-9.
Sanyal AJ, Harrison SA, Ratziu V, et al. The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. Hepatology. 2019;70(6):1913-27. PMID: 30993748; https://doi.org/10.1002/hep.30664.
Wirth KM, Sheka AC, Kizy S, et al. Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis: A Retrospective Cohort Analysis. Ann Surg. 2020;272(1):32-9. PMID: 32224733; https://doi.org/10.1097/SLA.0000000000003871.
Syn NL, Cummings DE, Wang LZ, et al. Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants. Lancet. 2021;397(10287):1830-41. PMID: 33965067; https://doi.org/10.1016/S0140-6736(21)00591-2.
Mózes FE, Lee JA, Selvaraj EA, et al. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71(5):1006-19. PMID: 34001645; https://doi.org/10.1136/gutjnl-2021-324243.
Jimenez LS, Marques RA, Gestic MA, et al. Non-Invasive Markers in Non-Alcoholic Fatty Liver Disease: Reliability Is Variable According to BMI Status. Obes Surg. 2021;31(8):3888-92. PMID: 33913073; https://doi.org/10.1007/s11695-021-05429-3.
Lee JH, Kim D, Kim HJ, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503-8. PMID: 19766548; https://doi.org/10.1016/j.dld.2009.08.002.
Angulo P, Hui JM, Marchesini G, et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846-54. PMID: 17393509; https://doi.org/10.1002/hep.21496.
Tai CM, Yu ML, Tu HP, et al. Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity. Surg Obes Relat Dis. 2017;13(4):686-92. PMID: 28089433; https://doi.org/10.1016/j.soard.2016.11.028.
